Study Shows Lumenate’s® Synergistic Power on Skin Structure and Collagen Protection
A preclinical study just published in Advances in Bioscience and Biotechnology demonstrates impressive benefits for skin structure when using Lycored...
Month: February 2024
Therap Services Debuts Secure Document Signing Module (SDS) with Enhanced Digital Security and Efficiency in Streamlining Healthcare Signatures
Therap Services, the national leader in providing HIPAA-compliant electronic documentation solutions to organizations and caregivers in the Long-Term Services and...
Koning Health Achieves UAE Regulatory Clearance, Paving the Way for Breast CT Commercialization in the Middle East
Koning Health, a pioneering medical imaging company, is thrilled to announce that it has received regulatory clearance from the Federal...
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad...
Philips extends leadership in virtually helium-free MRI with more than 1,000 systems installed, expanding patient access worldwide
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a significant milestone as it expands access...
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets...
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced...
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced...
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic...
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan...
